Minnesota Senate Bill SF3063

Minnesota 2025-2026 Regular Session

• Introduced: 3/27/25
• Refer: 3/27/25

Caption

Reverse auction procurement requirement modification for SEGIP pharmacy benefit contracts

Impact

In its enactment, SF3063 will significantly alter the legal framework surrounding PBMs in Minnesota. It will require PBMs to obtain a license from the commissioner of commerce, with increased application fees and renewal processes. By imposing fiduciary duties on these managers, the bill ensures that they prioritize the interests of health care providers and patients over their own profitability. The bill is anticipated to increase costs initially due to the heightened regulatory framework, but supporters believe that it will lead to lower drug prices over time as market inefficiencies are reduced.

Summary

SF3063 seeks to modify regulations governing pharmacy benefit managers (PBMs) in Minnesota. The bill aims to enhance transparency within the pharmaceutical procurement process by prohibiting spread pricing, which allows PBMs to charge health plans more for prescription drugs than what they reimburse pharmacies. This change is intended to address concerns regarding PBMs profiting at the expense of pharmacies and patients, thereby fostering a fairer pricing structure for prescription medications.

Contention

Despite its objective to enhance fairness and transparency, SF3063 is expected to encounter opposition from PBM representatives who argue that the regulations may impose undue burdens on their operations. Critics of the bill may express concerns that the increase in regulatory oversight could limit the ability of PBMs to manage costs effectively, potentially leading to higher overall healthcare costs. Additionally, there is the apprehension that while the bill seeks to protect local pharmacies, it might inadvertently create challenges for health plans, leading to reconsiderations about their relationships with PBMs.